Bioventus Inc Overview
Industry: Medical Devices
Sector: Healthcare
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina. Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injecti Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Bioventus Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net sales was $600M (reported); EPS was $0.75 (reported).
Net sales
$600M
reported
EPS
$0.75
reported
Operating income
$8.4M
+73% YoY
Net income
$3.9M
-219% YoY
What changed
- Net sales reported to $600M; EPS reported to $0.75.
- Operating income +73% YoY to $8.4M.
- Net income -219% YoY to $3.9M.
Guidance / outlook
the Company expects: • Adjusted EPS* of $0.75 to $0.79, an increase of $0.02 from previous guidance.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
8-K
May 06, 2026
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
Mar 05, 2026
Earnings release
Earnings release
Mar 05, 2026
SEC filing
10-K
Mar 05, 2026
SEC filing
10-Q
Nov 04, 2025
Earnings release
Earnings release
Nov 04, 2025
SEC filing
8-K
Nov 04, 2025
SEC filing
8-K
Aug 06, 2025
SEC filing
10-Q
Aug 06, 2025
Earnings release
Earnings release
Aug 06, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
Headline from Yahoo Finance: Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
Headline from Zacks Investment Research: Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
Bioventus (BVS) Upgraded to Buy: Here's Why
Headline from Yahoo Finance: Bioventus (BVS) Upgraded to Buy: Here's Why.
Should Value Investors Buy Bioventus (BVS) Stock?
Headline from Yahoo Finance: Should Value Investors Buy Bioventus (BVS) Stock?
Earnings Per Share
Score 2.00/5
Bioventus Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Edwards Lifesciences Corp
are companies with high ratings.
Return on Equity
Score 1.44/5
Bioventus Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.29/5
Bioventus Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 1.32/5
Bioventus Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios